Insider Buying: Inhibrx, Inc. (NASDAQ:INBX) CEO Acquires 13,037 Shares of Stock

Inhibrx, Inc. (NASDAQ:INBXGet Free Report) CEO Mark Lappe bought 13,037 shares of the stock in a transaction dated Monday, September 16th. The stock was purchased at an average cost of $17.13 per share, for a total transaction of $223,323.81. Following the acquisition, the chief executive officer now owns 705,548 shares of the company’s stock, valued at $12,086,037.24. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Mark Lappe also recently made the following trade(s):

  • On Thursday, September 12th, Mark Lappe acquired 26,963 shares of Inhibrx stock. The stock was purchased at an average price of $15.05 per share, with a total value of $405,793.15.
  • On Monday, September 9th, Mark Lappe bought 9,500 shares of Inhibrx stock. The shares were acquired at an average price of $15.21 per share, for a total transaction of $144,495.00.
  • On Friday, September 6th, Mark Lappe purchased 26,000 shares of Inhibrx stock. The stock was acquired at an average cost of $15.29 per share, with a total value of $397,540.00.
  • On Tuesday, September 3rd, Mark Lappe acquired 20,000 shares of Inhibrx stock. The shares were acquired at an average cost of $15.81 per share, for a total transaction of $316,200.00.
  • On Thursday, August 29th, Mark Lappe bought 10,000 shares of Inhibrx stock. The shares were bought at an average price of $14.03 per share, for a total transaction of $140,300.00.

Inhibrx Stock Down 1.3 %

Shares of INBX stock opened at $16.99 on Thursday. The stock has a fifty day moving average price of $13.87 and a 200 day moving average price of $23.42. Inhibrx, Inc. has a 1 year low of $10.80 and a 1 year high of $18.95.

Inhibrx (NASDAQ:INBXGet Free Report) last announced its earnings results on Tuesday, August 13th. The company reported $125.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.60) by $129.08. The business had revenue of $0.10 million for the quarter. As a group, equities analysts forecast that Inhibrx, Inc. will post 87.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, JMP Securities assumed coverage on shares of Inhibrx in a research note on Tuesday, July 23rd. They issued a “market perform” rating for the company.

Check Out Our Latest Research Report on Inhibrx

Hedge Funds Weigh In On Inhibrx

Institutional investors have recently made changes to their positions in the stock. Quadrant Capital Group LLC acquired a new stake in shares of Inhibrx during the fourth quarter valued at $26,000. Hennion & Walsh Asset Management Inc. boosted its stake in shares of Inhibrx by 2.5% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 30,561 shares of the company’s stock worth $1,068,000 after purchasing an additional 744 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Inhibrx by 8.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,812 shares of the company’s stock worth $518,000 after purchasing an additional 1,112 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Inhibrx by 7.0% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,920 shares of the company’s stock worth $766,000 after buying an additional 1,426 shares in the last quarter. Finally, Swiss National Bank raised its position in shares of Inhibrx by 8.5% in the first quarter. Swiss National Bank now owns 42,000 shares of the company’s stock valued at $1,468,000 after buying an additional 3,300 shares during the last quarter. 82.46% of the stock is owned by institutional investors and hedge funds.

About Inhibrx

(Get Free Report)

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.

Read More

Insider Buying and Selling by Quarter for Inhibrx (NASDAQ:INBX)

Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.